| Mucinous Adenocarcinomas1 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Site | # cases | CK7 | CK20 | CDX-2 (focal/hetero) | CDX-2 (diffuse/homo) | β-catenin | MUC-1 | Muc-2 | MUC-6 | ER | WT-1 | PAX-8 | |
| Lower GI | |||||||||||||
| Anus | 5 | 40% | 100% | 20% | 80% | 60% | 40% | 100% | 0% | 0% | 0% | 0% | |
| Colon | 18 | 6% | 100% | 22% | 78% | 61% | 11% | 100% | 6% | 0% | 0% | 0% | |
| Rectum | 19 | 26% | 95% | 21% | 79% | 68% | 11% | 100% | 11% | 0% | 0% | 0% | |
| Appendix | 27 | 41% | 96% | 89% | 11% | 11% | 15% | 100% | 0% | 0% | 0% | 0% | |
| Upper GI | |||||||||||||
| Ampulla | 4 | 25% | 25% | 75% | 25% | 25% | 50% | 100% | 75% | 0% | 0% | 0% | |
| Pancreas | 25 | 96% | 60% | 60% | 4% | 8% | 67% | 52% | 88% | 0% | 0% | 0% | |
| Stomach | 12 | 92% | 67% | 83% | 17% | 45% | 55% | 92% | 58% | 0% | 0% | 0% | |
| Bladder | 4 | 75% | 100% | 50% | 0% | 25% | 25% | 100% | 0% | 0% | 0% | 0% | |
| Breast | 18 | 100% | 0% | 0% | (not reported) | 0% | 100% | 100% | 50% | 89% | 50% | 0% | |
| Cervix | 5 | 100% | 0% | 0% | 0% | 0% | 100% | 40% | 100% | 60% | 0% | 20% | |
| Endometrium | 3 | 100% | 0% | 0% | 0% | 0% | 100% | 33% | 0% | 66% | 0% | 100% | |
| Ovary | 19 | 89% | 47% | 21% | 5% | 0% | 32% | 21% | 16% | 11% | 0% | 47% | |
| Lung | 16 | 100% | 31% | 13% | 0% | 0% | 94% | 25% | 31% | 0% | 0% | 0% | |
| 1Determining the Site of Origin of Mucinous Adenocarcinoma: An Immunohistochemical Study of 175 Cases Am J Surg Pathol vol 35, No 12, Dec 2011, pp1830-36 | |||||||||||||